REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT

Main Article Content

Vida Stankus
Brenda Hemmelgarn
Norm RC Campbell
Guanmin Chen
Finlay A McAlister
Ross T Tsuyuki

Keywords

Hypertension, combination products, cost-savings, adherence

Abstract

Objective


To quantify the cost-savings that could be realized by switching patients from two separate agents, ACE inhibitor/ARB and thiazide diuretic, to a fixed dose combination product.


 Methods


CompuScript and Longitudinal Rx (LRx) Insights data from IMS Health Canada for Oct 2006-Sept 2007 was used. From the LRx data, the proportion of patients taking both ACE inhibitors/ARBs and thiazide diuretics as two separate products was calculated to determine how many would qualify for a combination product. From the CompuScript data, the total number of prescriptions for ACE inhibitors and ARBs and the actual average dollar value per prescription for thiazide diuretics, ACE inhibitors, ARBs, and ACE inhibitor/ARB  with thiazide  diuretic  combination  products  was  used  to  determine  the  potential  cost savings of switching from two separate drugs to a combination product. As a sensitivity analysis, the proportion of patients receiving two separate products who could be switched to a combination product was varied from 60-100%. This analysis was done for Alberta and Canada.


 Results


The conversion  of ACE inhibitor/ARB  and thiazide diuretic as two separate agents to a combination product could potentially result in a yearly cost-savings of $27 to $45 million for Canada ($1.1 to $1.9 million for Alberta), based on 60-100% conversion to a combination product.


 Conclusions


The present analysis has shown that a simple intervention of converting patients receiving separate ACE inhibitor/ARB  and  thiazide  diuretic  prescriptions  to  a  single  combination  product  prescription  will produce  substantial  cost-savings  for the health  care system  and simplify  the medication  regimen  for patients.

Abstract 181 | PDF Downloads 91

References

1. Khan NA, Hemmelgarn B, Herman RJ et al; for the Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: Part 2-Therapy. Can J Cardiol 2008;24(6):465-476.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
3. Hansson L, Zanchetti A, Carruthers SG et al; for the HOT Study Group. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
4. Campbell NRC, McAlister FA, Duong-Hua M, et al. Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. Can J Cardiol 2007;23(10):783-787.
5. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120:713-719.
6. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCI versus comparable component-based therapy. Congest Heart Failure 2003;9:324-32.
7. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;23:239-45.
8. DiTusa L, Luzier AB, Jarosz DE, et al. Treatment of hypertension in a managed care setting. Am J Manag Care 2001;7:520-4.
9. Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25mg in fixed combination in hypertensive patients not controlled by candesartan 32mg plus HCTZ 25mg in free combination. Curr Med Res Opin 2007;23(11):2877-85.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003;326:1427-34.
11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-40.
12. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT; for the SCRIP-HTN Investigators. A Randomized Trial of the Effect of Community Pharmacist and Nurse Care on Improving Blood Pressure Management in Patients With Diabetes Mellitus. Arch I nt Med 2008;168(21):2355-2361.